Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Anixa Biosciences Inc ANIX
$3.08
▼ -2.53%
($-0.08)
⬇️ Below Yest. Low
Open
$3.13
Prev Close
$3.16
Day Range
$3.04 – $3.22
52W Range
$2.32 – $5.46
Market Cap
$109.85M
Beta
0.52
EPS (TTM)
$-0.31
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1983-10-07 |
| Shares Out. | 34,760,000 |
| Website | anixa.com/ ↗ |
| Phone | 13026587581 |
| Employees | 4 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$2.6M |
| Free Cash Flow | -$7.4M |
| Total Assets | $15.1M |
| Total Liabilities | $1.9M |
| Equity | $13.2M |
About Anixa Biosciences Inc
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Anixa Biosciences Inc is a publicly traded company under the ticker symbol ANIX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-11-01)